See If You Qualify

About the
EPCORE NHL-5 Study

The EPCORE NHL-5 Study is evaluating the safety and tolerability of a primary investigational drug in combination with other drugs for adults with non-Hodgkin lymphoma (NHL). The study is meant for those with specific types of treatment-naïve, relapsed, or refractory NHL. 

  • Treatment-naïve: You have not had any treatments for this type of cancer 
  • Relapsed: Your cancer previously responded to therapy but progressed 6 months or later after completing therapy
  • Refractory: Your cancer either progressed during therapy, did not respond to prior therapy, or progressed within 6 months after completing therapy (including maintenance therapy)

You may be able to take part in the EPCORE NHL-5 Study if you:

  • Are at least 18 years old
  • Have a diagnosis of one of the following non-Hodgkin lymphomas:
  • Diffuse large B-cell lymphoma (DLBCL), including:
  • Treatment-naïve DLBCL
  • Relapsed or refractory DLBCL
  • Relapsed or refractory follicular lymphoma (FL)
  • Mantle cell lymphoma (MCL), including;
  • Treatment-naïve MCL
  • Relapsed or refractory MCL

If you are interested in participating, the study doctor and staff will review additional eligibility criteria with you.

Study Overview

Different investigational combinations of drugs will be tested in this study and the study doctor will choose the combination that is right for you. These combinations of drugs are investigational because they have not been approved to treat these diseases by the regulatory authority in your country. There is no placebo in this study, which means all participants will receive study treatment.

There are multiple study treatment groups, or arms, for this study. You will be assigned to a group depending on your disease.

The primary investigational drug will be given as a subcutaneous injection (under the skin). The other drugs will either be given through an intravenous infusion (delivered through a tiny tube into the vein) or as a capsule or tablet that will be taken by mouth.

The study treatment period may last from 24 weeks to 2 years or more depending on your study treatment arm and how well the study drug(s) work for you. Total study duration will depend on each participant’s response to the study drug(s).

For additional information: Download the EPCORE NHL-5 Study Guide.

Download Study Guide
This research study is evaluating the safety and effectiveness of a drug for a specific use that is currently not approved by regulatory health authorities. 

Great—let’s get you back to the homepage.

Back to Home

Quick Facts on Non-Hodgkin Lymphoma2

  • Non-Hodgkin lymphoma (NHL) affects the lymphatic system, which includes a network of vessels, nodes, and ducts that help to maintain body fluid levels and remove cellular waste. It is more common than HL.
  • There are two broad categories of NHLs:
  • B-cell lymphomas (which account for about 85% of all NHLs)
  • T-cell lymphomas (which account for about 15% of all NHLs)
  • In terms of growth, NHLs are broken down into two categories:
  • Indolent = slow-growing
  • Aggressive = fast-growing
  • There are more than 90 types of NHLs overall. Although NHLs have traits in common, they may have different growth patterns, different appearances under a microscope, and different responses to treatment.
  • Symptoms include swollen lymph nodes, fever, night sweats, fatigue, and weight loss.

Quick Facts on Mantle Cell Lymphoma (MCL)12

  • Mantle cell lymphoma is a rare form of B-cell non-Hodgkin lymphoma (NHL). It is considered a B-cell lymphoma because it affects the B-lymphocytes. Lymphocytes help your body fight infections.
  • This rare condition affects only about 1 in 200,000 people each year.
  • Within lymph nodes, there are compartments called lymphatic nodules. There is a ring of small lymphocytes that surround the center of each nodule—this is the mantle zone. With MCL, your body overproduces lymphocytes in the mantle zone.
  • MCL is an aggressive NHL, which means that it progresses quickly. It typically affects older adults between 60 and 70 years old.
  • The most common symptoms of MCL include swollen lymph nodes, fatigue, night sweats, fever, and unexplained weight loss.
  • MCL is typically diagnosed through a combination of physical examination, blood tests, imaging studies, and a lymph node biopsy.

Quick Facts on Follicular Lymphoma

  • Follicular lymphoma is a type of cancer that affects white blood cells called B-lymphocytes. Lymphocytes help your body fight infections.
  • Follicular lymphoma is a non-Hodgkin lymphoma (NHL). It is also a B-cell lymphoma because it affects the B-lymphocytes.
  • Follicular lymphoma accounts for 20–40% of all NHLs in Western Europe and the United States.7
  • Follicular lymphoma is an indolent NHL, which means that it progresses slowly. People with follicular lymphoma may not notice any obvious symptoms of it.
  • Symptoms include swollen lymph nodes (especially in the part of the body where the lymphoma starts to grow), fever, night sweats, fatigue, and weight loss.8
  • Incidence of follicular lymphoma increases with age, and it is the most common form of indolent NHL.9

Quick Facts on Diffuse Large B-Cell Lymphoma

  • Diffuse large B-cell lymphoma (DLBCL) is the most common of all NHLs worldwide.4
  • DLBCL is considered an aggressive or fast-growing NHL. It is also a B-cell lymphoma because it affects white blood cells called B-lymphocytes. Lymphocytes help your body fight infections.
  • Although DLBCL can affect children, and is one of the most common NHL subtypes in children,5 people over the age of 60 are most commonly affected by DLBCL.4
  • For many with DLBCL, the first symptom is rapid swelling in the neck, underarms, or groin. The swelling is caused by enlarged lymph nodes.6
  • Treatment will depend on the subtype of DLBCL. For example, there are subtypes that mostly occur in younger patients and affect the chest cavity, while there are other subtypes that only affect the brain.6